Literature DB >> 25370803

Relationship between procalcitonin serum levels and functional outcome in stroke patients.

Wen-Jing Deng1, Rui-Le Shen2, Meng Li1, Jun-Fang Teng3.   

Abstract

To determine whether serum procalcitonin (PCT) levels at admission were associated with short-term functional outcome after acute ischemic stroke (AIS) in a cohort Chinese sample. We prospectively studied 378 patients with AIS who were admitted within 24 h after the onset of symptoms. PCT and NIH stroke scale (NIHSS) were measured at the time of admission. Short-term functional outcome was measured by modified Rankin scale (mRS) 90 days after admission. The results indicated that the serum PCT levels were significantly higher in AIS patients as compared to normal controls (P < 0.0001). In the 114 patients with an unfavorable functional outcome, serum PCT levels were higher compared with those in patients with a favorable outcome (2.40 (IQR, 1.10-3.69) ng/mL and 0.42 (IQR, 0.10-1.05) ng/mL, respectively, P < 0.001). PCT was an independent prognostic marker of functional outcome [odds ratio (OR) 3.45 (2.29-4.77), adjusted for the NIHSS and other possible confounders] in patients with ischemic stroke, added significant additional predictive value to the clinical NIHSS score. In receiver operating characteristic curve analysis, the prognostic accuracy of PCT was higher compared to Hs-CRP and NIHSS score. PCT is an independent predictor of short-term functional outcome after ischemic stroke in Chinese sample even after correcting for possible confounding factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25370803     DOI: 10.1007/s10571-014-0131-0

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  30 in total

Review 1.  Physiology and genetics of procalcitonin.

Authors:  P Maruna; K Nedelníková; R Gürlich
Journal:  Physiol Res       Date:  2000       Impact factor: 1.881

Review 2.  The global stroke initiative.

Authors:  Ruth Bonita; Shanthi Mendis; Thomas Truelsen; Julien Bogousslavsky; James Toole; Frank Yatsu
Journal:  Lancet Neurol       Date:  2004-07       Impact factor: 44.182

Review 3.  Treating patients with severe sepsis.

Authors:  A P Wheeler; G R Bernard
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

4.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.

Authors:  S Harbarth; K Holeckova; C Froidevaux; D Pittet; B Ricou; G E Grau; L Vadas; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

5.  The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study.

Authors:  Blanca Fuentes; José Castillo; Belén San José; Rogelio Leira; Joaquín Serena; José Vivancos; Antonio Dávalos; Antonio Gil Nuñez; José Egido; Exuperio Díez-Tejedor
Journal:  Stroke       Date:  2008-12-18       Impact factor: 7.914

6.  Measurements of acute cerebral infarction: lesion size by computed tomography.

Authors:  T Brott; J R Marler; C P Olinger; H P Adams; T Tomsick; W G Barsan; J Biller; R Eberle; V Hertzberg; M Walker
Journal:  Stroke       Date:  1989-07       Impact factor: 7.914

7.  High plasma glutamate levels are associated with poor functional outcome in acute ischemic stroke.

Authors:  Xiang-en Meng; Na Li; Da-Zhi Guo; Shu-Yi Pan; Hang Li; Chen Yang
Journal:  Cell Mol Neurobiol       Date:  2014-09-05       Impact factor: 5.046

8.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

9.  Procalcitonin and C-reactive protein levels at admission as predictors of duration of acute brain dysfunction in critically ill patients.

Authors:  Stuart McGrane; Timothy D Girard; Jennifer L Thompson; Ayumi K Shintani; Alison Woodworth; E Wesley Ely; Pratik P Pandharipande
Journal:  Crit Care       Date:  2011-03-02       Impact factor: 9.097

10.  Copeptin, procalcitonin and routine inflammatory markers-predictors of infection after stroke.

Authors:  Felix Fluri; Nils G Morgenthaler; Beat Mueller; Mirjam Christ-Crain; Mira Katan
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more
  6 in total

1.  Serum Procalcitonin Levels are Associated with Clinical Outcome in Intracerebral Hemorrhage.

Authors:  Dingxiu He; Yun Zhang; Biao Zhang; Wei Jian; Xiaojian Deng; Yi Yang; Tao Xiao; Hanyang Yu; Shuyin Wen; Kaisen Huang
Journal:  Cell Mol Neurobiol       Date:  2017-08-20       Impact factor: 5.046

Review 2.  Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns.

Authors:  Alejandro Bustamante; Alba Simats; Andrea Vilar-Bergua; Teresa García-Berrocoso; Joan Montaner
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 3.  Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke.

Authors:  Aldo Bonaventura; Luca Liberale; Alessandra Vecchié; Matteo Casula; Federico Carbone; Franco Dallegri; Fabrizio Montecucco
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

4.  Procalcitonin and mortality in status epilepticus: an observational cohort study.

Authors:  Raoul Sutter; Martina Valença; Sarah Tschudin-Sutter; Stephan Rüegg; Stephan Marsch
Journal:  Crit Care       Date:  2015-10-09       Impact factor: 9.097

5.  Procalcitonin as a Biomarker for Malignant Cerebral Edema in Massive Cerebral Infarction.

Authors:  Yan Zhang; Gang Liu; Yuan Wang; Yingying Su; Rehana K Leak; Guodong Cao
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

6.  Procalcitonin as a prognostic marker of patients with acute ischemic stroke.

Authors:  Ling Yan; Shuling Wang; Lanlan Xu; Zhen Zhang; Pu Liao
Journal:  J Clin Lab Anal       Date:  2020-03-20       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.